Celanese Corporation
NYSE:CEChemicals
-$0.24 today
- Market cap
- $5.29B
- Beta
- 0.74
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$9.98
- Dividend yield
- 0.24%
Volume 1.38M
Average 2.09M
CE Other Financing Activities
Financing cash flows not reported separately.
Celanese CorporationNYSE: CE
Other Financing Activities · Q2 FY2026 · quarter ended Jun 2026
Other financing activities turns positive
Q2 FY2026 other financing activities was $4M, compared with -$10M a year earlier. Trailing-twelve-month other financing activities was -$93M. Over 3 fiscal years it compounded at +0.4% a year.
Context
- Other financing activities amounted to 1.9% of revenue in FY2025, up 1.3 pp from a year earlier.
- Other financing activities grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly other financing activities holds near $4M or moves back toward the trailing-twelve-month quarterly average of -$23.25M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Financing Activities history
USD · from the cash flow
- Latest · FY2025
- (177M) USD
- Year-over-year change
- -200.0%
| Period | Period end | Other Financing Activities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (177M) | -200.0% |
| FY2024 | 2024-12-31 | (59M) | +6.3% |
| FY2023 | 2023-12-31 | (63M) | +64.0% |
| FY2022 | 2022-12-31 | (175M) | -23.2% |
| FY2021 | 2021-12-31 | (142M) | — |
Other Financing Activities vs competitors
How CE compares with its peers on the latest reported figures
- Peers report in different currencies, so other financing activities is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -10.6% is the 4th highest of 10, against a peer median of -74.7%.
- Other financing activities amounts to 1.0% of revenue for CE, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2026 | ZAR 3.24B ZAR | +1695.1% | +348.3% | 1.2% | |
| LTM Jun 2026 | $93M USD | -10.6% | +0.4% | 1.0% | |
| LTM Jun 2026 | $66.58M USD | — | -37.9% | 3.4% | |
| LTM Jun 2026 | $47M USD | -17.5% | +37.3% | 1.3% | |
| LTM Sep 2026 | $18.51M USD | -591.7% | — | 1.7% | |
| LTM Jun 2026 | $6.08M USD | +50.9% | +28.0% | 0.4% | |
| LTM Mar 2026 | $4.28M USD | -74.7% | — | — | |
| LTM Mar 2026 | $3.77M USD | +121.6% | — | 0.3% | |
| LTM Sep 2026 | $2.14M USD | -220.1% | — | 0.2% | |
| LTM Jun 2026 | $1M USD | -93.8% | -35.2% | 0.1% | |
| LTM Aug 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding CE) | — | -74.7% | +28.0% | 0.4% | |
Competitors are the stored peer set for CE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.89B | 1.9B | 1.96B | (1.51B) | (1.14B) |
| Depreciation & Amortization | 378M | 478M | 711M | 823M | 786M |
| Deferred Income Tax | 13M | (835M) | (967M) | 216M | (278M) |
| Stock-Based Compensation | 95M | 60M | 40M | 32M | 0 |
| Change in Working Capital | (488M) | 280M | 516M | (204M) | 235M |
| Accounts Receivables | (396M) | 218M | 105M | 92M | 213M |
| Inventory | (367M) | (253M) | 398M | 11M | 154M |
| Accounts Payables | 353M | (84M) | 20M | (234M) | 26M |
| Other Working Capital | (78M) | 399M | (7M) | (73M) | (158M) |
| Other Non-Cash Items | (131M) | (66M) | (365M) | 1.61B | 1.55B |
| Operating Cash Flow | 1.76B | 1.82B | 1.9B | 966M | 1.15B |
| Capital Expenditures | (467M) | (543M) | (568M) | (435M) | (343M) |
| Acquisitions (Net) | (1.12B) | (10.54B) | 532M | 0 | 21M |
| Purchases of Investments | 467M | 0 | 0 | 0 | 0 |
| Sales of Investments | 516M | 0 | 0 | 17M | 0 |
| Other Investing Activities | (520M) | (57M) | (98M) | (52M) | (27M) |
| Investing Cash Flow | (1.12B) | (11.14B) | (134M) | (470M) | (349M) |
| Debt Repayment | 404M | 10.78B | (1.09B) | (948M) | (323M) |
| Common Stock Issued | 0 | 0 | 0 | 1M | 0 |
| Common Stock Repurchased | (1B) | (17M) | 0 | 0 | 0 |
| Dividends Paid | (304M) | (297M) | (305M) | (307M) | (13M) |
| Other Financing Activities | (142M) | (175M) | (63M) | (59M) | (177M) |
| Financing Cash Flow | (1.04B) | 10.29B | (1.46B) | (1.31B) | (513M) |
| Effect of Forex Changes | (15M) | 4M | (12M) | (26M) | 17M |
| Net Change in Cash | (419M) | 972M | 297M | (843M) | 301M |
| Free Cash Flow | 1.29B | 1.28B | 1.33B | 531M | 803M |
Celanese Corporation
NYSE:CE
Intrinsic Alpha fair value
Locked
Current Price
$48.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.